Brief: Medipost Inc. Submits Ind Amendment With U.S. Food And Drug Administration To Initiate Phase Iii Trial
13/02/2026 13:47
Feb 13 (Reuters) - Medipost Co Ltd 078160.KQ: MEDIPOST INC. SUBMITS IND AMENDMENT WITH U.S. FOOD AND DRUG ADMINISTRATION TO INITIATE PHASE III TRIAL MEDIPOST:IND AMENDMENT SUBMITTED TO FDA TO SUPPORT INITIATING PHASE III CLINICAL TRIAL EVALUATING INVESTIGATIONAL CELL THERAPY FOR KNEE OSTEOARTHRITIS Source text: ID:nBw2Sq4QTa Further company coverage: 078160.KQ ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Medipost Co
See all newsBrief: Medipost's Cartistem® Meets All Primary And Secondary Endpoints In Japan Phase 3 Trial And Demonstrates Statistically Significant Efficacy Gains Versus Active Control
Brief: Medipost Inc. Submits Ind Amendment With U.S. Food And Drug Administration To Initiate Phase Iii Trial
Brief: Medipost Co Q3 Operating Profit 2 Billion Won, Swings To Profit From Year Earlier
Brief: Medipost To Conduct Capital Increase Of 120 Billion Won
Brief: Medipost Co To Acquire 46 Billion Won Worth Of Shares In Unit Medipost America